A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 2'-OMe / 2'-O-methyl

[Related PubMed/MEDLINE]
Total Number of Papers: 57
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   2'-OMe  (>> Co-occurring Abbreviation)
Long Form:   2'-O-methyl
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 2'-O-Methyl modified guide RNA promotes the single nucleotide polymorphism (SNP) discrimination ability of CRISPR-Cas12a systems. gRNA, SNP
2022 Modelling aptamers with nucleic acid mimics (NAM): From sequence to three-dimensional docking. LNA, NAM, NAM, SELEX
2022 Phosphorothioate modification improves exon-skipping of antisense oligonucleotides based on sulfonyl phosphoramidates in mdx mouse myotubes. AOs, PS
2022 siRNA Seed Region Is Divided into Two Functionally Different Domains in RNA Interference in Response to 2'-OMe Modifications. miRNAs, RNAi, siRNA
2022 Structural Fingerprinting of siRNA Therapeutics by Solution NMR Spectroscopy. FDA, mRNA, NMR, PS, siRNA
2022 The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2'-O-Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs. ASOs, MsPA, PS
2021 A Small RNA-Seq Protocol with Less Bias and Improved Capture of 2'-O-Methyl RNAs. miRNAs, NGS, sRNAs, TS
2021 An Influence of Modification with Phosphoryl Guanidine Combined with a 2'-O-Methyl or 2'-Fluoro Group on the Small-Interfering-RNA Effect. PG, siRNA
2021 Intramuscular Evaluation of Chimeric Locked Nucleic Acid/2'OMethyl-Modified Antisense Oligonucleotides for Targeted Exon 23 Skipping in Mdx Mice. AON, DMD, LNA
10  2021 Sequence-dependent inhibition of cGAS and TLR9 DNA sensing by 2'-O-methyl gapmer oligonucleotides. ASOs, cGAS, TLR
11  2021 Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer. A-to-I, ASOs, AZIN1, ECS, PS
12  2020 Development of Novel Chemically-Modified Nucleic Acid Molecules for Efficient Inhibition of Human MAPT Gene Expression. AOs, MAPT, PS
13  2020 DNA Polymerase Variants with High Processivity and Accuracy for Encoding and Decoding Locked Nucleic Acid Sequences. 2',4'-BNA, KOD, KOD, LNA, XNAs
14  2020 Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists. 2'-MOE, ASOs, LNA
15  2019 Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. 2'-MOE, cEt, LNA, PS-ASOs
16  2019 Improving Small RNA-seq: Less Bias and Better Detection of 2'-O-Methyl RNAs. miRNAs, NGS, sRNAs
17  2019 Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro. AMD, AO, DMD, FDA, LNA, PMO, PS
18  2019 Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy. 3'UTR, ASOs, LNA
19  2018 Antimicrobial assessment of phage therapy using a porcine model of biofilm infection. FISH, LNA, PNA
20  2018 Chemical Modification of the siRNA Seed Region Suppresses Off-Target Effects by Steric Hindrance to Base-Pairing with Targets. AGO, CM, LNA, siRNA, SM
21  2018 Effective gene silencing activity of prodrug-type 2'-O-methyldithiomethyl siRNA compared with non-prodrug-type 2'-O-methyl siRNA. MDTM, RISC, siRNAs
22  2018 Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice. 2'-O-MOE, ASGR, ASO, cEt BNA, FHNA, LNA
23  2018 Single base resolution mapping of 2'-O-methylation sites in human mRNA and in 3' terminal ends of small RNAs. ---
24  2018 Systematic comparison of small RNA library preparation protocols for next-generation sequencing. miRNA, MRL, PEG, piRNA, siRNA, sRNAs
25  2017 Effective Anti-miRNA Oligonucleotides Show High Releasing Rate of MicroRNA from RNA-Induced Silencing Complex. AMOs, miRNAs, RISCs
26  2016 Application of locked nucleic acid-based probes in fluorescence in situ hybridization. FISH, LNA
27  2016 Efficient and specific inhibition of plant microRNA function by anti-microRNA oligonucleotides (AMOs) in vitro and in vivo. AMOs, miRNAs
28  2016 Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and d-altritol nucleic acid-modified 2'-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro. ANA, AO, CeNA, DMD, HNA, PS
29  2016 Noninvasive visualization of microRNA-155 in multiple kinds of tumors using a radiolabeled anti-miRNA oligonucleotide. AMO-155, HPLC, PS
30  2016 Structural basis for m7G recognition and 2'-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I. ds, m7G, RIG-I
31  2014 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. GRAMD1B, siRNA
32  2014 Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides. PS, SSOs
33  2014 Optimizations of siRNA design for the activation of gene transcription by targeting the TATA-box motif. IL-2, miRNAs, nts, siRNAs
34  2014 Sequence-dependent off-target inhibition of TLR7/8 sensing by synthetic microRNA inhibitors. LNA, miRNA, TLR
35  2013 Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. AON, DMPK, ENA, PT
36  2013 In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal nanoparticle. AMOs, miRNAs
37  2013 Site-specific labeling of RNA. ---
38  2012 Chemical modification study of antisense gapmers. LNA, MOE
39  2012 Collision-induced dissociation of oligonucleotide anions fully modified at the 2'-position of the ribose: 2'-F/-H and 2'-F/-H/-OMe mix-mers. CID
40  2011 Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. ---
41  2011 Fluorescence cross-correlation spectroscopy reveals mechanistic insights into the effect of 2'-O-methyl modified siRNAs in living cells. RISC, RNAi
42  2009 Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. shRNAs, siRNAs, sshRNAs
43  2009 Treating respiratory viral diseases with chemically modified, second generation intranasal siRNAs. PIV, RNAi, RSV, siRNA
44  2008 A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. miRNA, RNAi, siRNA
45  2008 An affinity oligonucleotide displacement strategy to purify ribonucleoprotein complexes applied to human telomerase. snRNP
46  2008 Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice. CG, DMD, ESOs, NG, PEG, PEI, TA
47  2007 2'-O-methyl-modified RNAs act as TLR7 antagonists. Flt3L DCs, human PBMCs, IFN-alpha, IL-6, siRNA, ssRNA, TLR
48  2007 Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. DTC-Apo, HBV, siRNA
49  2006 Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. DMED, LNAs, PS
50  2006 The development of bioactive triple helix-forming oligonucleotides. AE, TFOs
51  2005 Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. apoB, siRNA
52  2005 Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. PS, RISC, RNAi, siRNAs
53  2004 Hydration of short DNA, RNA and 2'-OMe oligonucleotides determined by osmotic stressing. ---
54  2003 Enhancement and inhibition by 2'-O-hydroxyethyl residues of gene targeting mediated by triple helix forming oligonucleotides. 2'-AE, 2'-HE, TFOs
55  2002 The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2'-O-methyl modifications. g5p, prC
56  2001 Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. 2'-O-MOE, EGFP, Lys, PNA, pre-mRNA
57  2000 Pyrimidine motif triplexes containing polypurine RNA or DNA with oligo 2'-O-methyl or DNA triplex forming oligonucleotides. TFOs